Drug Database
Back to search

Poland· PL-100390647

Kisqali

A ribociclib product containing ribociclibum, registered in Poland by Novartis Europharm Limited. The same ATC class is registered in 12 of our 19 countries.

ATC L01EF02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedKisqaliATCL01EF02REGISTER NO.PL-100390647PACKS LISTED8CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ribociclibumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ribociclib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EF02 (ribociclib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search ribociclib products by name

Ribociclib · ATC L01EF02

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ribociclib costs, country by country.

Normalised to the WHO defined daily dose (0.45 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ribociclib · price per daily dose (0.45 g)

USD · FX 28 Sept 2026

  • CH Switzerland$111.31
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Ribociclibum
Manufacturer
Novartis Europharm Limited
Country
Poland (PL)
ATC code
L01EF02
ATC class
Ribociclib
Defined daily dose
0.45 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 8

  • gtin
    05909991336769
  • gtin
    05909991336776
  • gtin
    05909991336783
  • gtin
    05909991336790
  • gtin
    05909991344948
  • gtin
    05909991344955
  • gtin
    07613421176259
  • gtin
    07613421186548

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

679 interactions on record for ribociclib.

Graded by severity as the source publishes them — 315 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ribociclib against other medicinesHow interaction checks work

Ribociclib · interactions on record

679 records

  • 315 severe
  • 347 moderate
  • 17 minor

Most severe, free to view

  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • DolasetronA04AA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ribociclib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ribociclib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Kisqali
  • Liechtenstein · Kisqali
  • Norway · Kisqali

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fbe4ffda-a104-4e73-b7ef-350df975363b
GET /v1/drugs/fbe4ffda-a104-4e73-b7ef-350df975363b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "200 mg",
  "packaging": "05909991336769 ¦ Rpz ¦ EU/1/17/1221/005; EU/1/17/1221/006 ¦ 123340\n63 tabl.\n05909991336776 ¦ Rpz ¦ EU/1/17/1221/007; EU/1/17/1221/008 ¦ 123343\n63 tabl. (op. zbiorcze)\n05909991336783 ¦ Rpz ¦ EU/1/17/1221/001; EU/1/17/1221/002 ¦ 124896\n21 tabl.\n05909991336790 ¦ Rpz ¦ Skasowane ¦ EU/1/17/1221/003; EU/1/17/1221/004 ¦ 124898\n42 tabl.\n05909991344948 ¦ Rpz ¦ EU/1/17/1221/009; EU/1/17/1221/010 ¦ 124911\n126 tabl. (op. zbiorcze)\n05909991344955 ¦ Rpz ¦ EU/1/17/1221/011; EU/1/17/1221/012 ¦ 124913\n189 tabl. (op. zbiorcze)\n07613421176259 ¦ Rpz ¦ Skasowane ¦ EU/1/17/1221/003; EU/1/17/1221/004 ¦ 153196\n42 tabl.\n07613421186548 ¦ Rpz ¦ EU/1/17/1221/003; EU/1/17/1221/004 ¦ 158084\n42 tabl.",
  "substance": "Ribociclibi succinas 200 mg",
  "common_name": "Ribociclibum",
  "pl_product_id": "100390647",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about ribociclib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console